Loading...
•
Dec 31, 2020
Ampio Q4 2020 Earnings Report
Ampio reported financial results for Q4 2020 and provided a business update.
Key Takeaways
Ampio Pharmaceuticals reported its annual financial results for the year ended December 31, 2020. The company's cash and cash equivalents totaled $17.3 million, and research and development expenditures were $9.2 million.
FDA recommended a randomized, double-blinded, placebo-controlled Phase II trial for IV and Inhaled Ampion.
Proposal submitted to FDA regarding Osteoarthritis of the Knee (OAK) Phase III clinical trial.
Cash and cash equivalents totaled $17.3 million at December 31, 2020.
Research and development expenditures were $9.2 million for the year ended December 31, 2020.
Forward Guidance
Ampio expects to have sufficient cash to fund operations through the first quarter of 2022.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...